Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design
OncLive TV
Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits
Advertisement
Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium
Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment
Dr. Ken Y. Yoneda from UC Davis Cancer Center Discusses Pulmonary Nodules
Dr. Donald McDonald from UCSF Comprehensive Cancer Center Explains Approved Angiogenesis Inhibitors
Advertisement
Dr. Heather Wakelee from Stanford Clinical Cancer Center on Explaining Adjuvant Therapy to Patients
Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity
Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy
Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor
Dr. Giorgio Scagliotti from University of Turin Discusses EGFR Mutations in non-small cell lung cancer
Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment
Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms
Dr. Heather Wakelee from Stanford Clinical Cancer Center on Adjuvant Therapy in Elderly NSCLC Patients
Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome
Dr. J. Michael Dixon from University of Edinburgh on Advances in Breast Cancer Systemic Therapy
Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors
Dr.Ken Yoneda from UC Davis Cancer Center Discusses Integrating the Pulmonologist into Multidisciplinary Practice
Dr. Jeffrey Bradley from Washington University School of Medicine Discusses Key Lung Cancer Topics
Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials
Dr. Hope S. Rugo from UCSF Cancer Center on the Future of Angiogenesis in Breast Cancer
Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment
Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors
Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy
Dr. J. Michael Dixon from the University of Edinburgh on Advances in Breast Cancer Axillary Node Procedures
Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors
Dr. J. Michael Dixon from the University of Edinburgh Discusses Advances in Breast Cancer Treatment
Dr. Paul Baas from the Netherlands Cancer Institute on the Standard of Care for Mesothelioma Patients
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5